Fosmanogepix treatment for coccidioidomycosis under an expanded access program.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 42015519.
- Also identified by DOI 10.1093/cid/ciag271.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Coccidioidomycosis is an invasive fungal infection that can disseminate and cause severe disease. Fosmanogepix ("gepix"), a first-in-class antifungal available via expanded access (NCT06433128), was successful in 8/11 patients (meningitis, 6/8 [75%]; non-meningeal dissemination, 2/3 [66%]) and was well tolerated for a median treatment duration of 208 days.